|
Post by longinvstr on Nov 9, 2015 13:08:25 GMT -5
I thought davinci had sold a while back and moved on? Is this sort of like leaving the stadium in disgust after the first quarter and then watching the live stream on ESPN with the corresponding commentary? The critters love to resurrect coincidentally on bear raid days....the funniest part is let's take the OP's thread title and turn it around...is risk/reward skewed more heavily for short or long potential at this juncture... downside vs. upside....are you freaking kidding me, oh and BTW...SI comes out after close tomorrow... still close to 50% in debt I'm sure I suspect shorty must feel a wee sense of failure. Targeting a buck and only getting ~$2.50 must be disappointing, esp. given the interest, entrance fee to play. They've missed target by 150%. The Sunday DG release by GS reeks of desperation and last gasp effort. There can only be "positive" news in the CC this evening. There can only be a positive effect on PPS from the new, impending demand at the TASE. And, I'd bet a double-dip cone we have Technosphere partnership(s) announced in the next 30 days. I think it's rational to expect a near-term steepening of the scrip count curve too. Game's far from over but this bear raid's exhausted.
|
|
|
Post by kc on Nov 9, 2015 13:26:28 GMT -5
I thought davinci had sold a while back and moved on? Is this sort of like leaving the stadium in disgust after the first quarter and then watching the live stream on ESPN with the corresponding commentary? Well if I have lost all the games of the season then what do I get for my draft pick?
|
|
|
Post by charlespk on Nov 9, 2015 14:48:08 GMT -5
I guess , I joined the " idiots " list today .
I bought some more , to 1) average down and 2) , I don't believe Al , who spent 10 year to get this approved and a billion dollars , and persisted despite CRL's , will let this go down the tubes .
I am an optimist or an idiot , but for MNKD pay cash , when you are left with so little capital now , that you would be one quarter away from having no money , does not make sense.
They must know some money is coming , via milestone payment or Al will expand the line of credit or some TS partner is coming .
If I lose all , I lose all , it will be significant for me, but I could not pass buying more today . time will tell .
Waiting for the conference call .
|
|
|
Post by spiro on Nov 9, 2015 14:55:56 GMT -5
Joey,
Spiro doesn't know who's right today, but he feels like rejuvenated roadkill at the moment. They were bringing the skewers to get him a few hours ago.
|
|
|
Post by dreamboatcruise on Nov 9, 2015 15:27:21 GMT -5
MNKD is no longer a risk reward investment as there's now mostly risk and very little real or actual rewards now or in the near term. While that will rankle many here it should be considered for those interested in preserving capital. While not disputing that there is a lot of risk, the statement about it not being risk/reward trade off is obviously off base. If the reward was already now happening or obvious in the near term... there would basically be very little risk given this is highly regulated pharma space. We all know if Afrezza is successful and MNKD hasn't suffered significant further dilution before it happens, the company is worth a heck of a lot more than its current market cap. This is classic high risk vs high reward type of investment. You don't get high reward potential, low risk. It's not an investment for everyone, that is for sure. Despite having FDA approval, I'd say MNKD has a risk/reward profile more akin to a bipharma company that is still pre-approval... still an opportunity to make a killing, with the risk of losing most/all.
|
|
|
Post by jbe on Nov 9, 2015 16:12:26 GMT -5
All that matters at this point in time is, where is management going to get money to stay in business?
This the only issue that has to be addressed in this conference call.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 9, 2015 17:48:59 GMT -5
Cash good til 2017 per matt today. With 32 million in cash and 68 million in loans plus whatever they get from the direct/market sales to the Israelis should get them to 2017 pretty easily. Maybe sales will pick up and start contributing to the bottom line next year but solving the insurance blockage sounds like it'll be the elephant in the room that needs fixing. Oh well, would love to take another long position but I see more landmines than roses in the pathway over the next year or two.
|
|